CN Patent

CN111225662B — 药物组合物和剂型

Assigned to Ignyta Inc · Expires 2022-11-22 · 3y expired

What this patent protects

本公开涉及包括N‑[5‑(3,5‑二氟苄基)‑1H‑吲唑‑3‑基]‑4‑(4‑甲基‑哌嗪‑1‑基)‑2‑(四氢‑2H‑吡喃‑4‑基氨基)‑苯甲酰胺和聚合物的药物组合物，包括调配物的剂型和治疗患有癌症的受试者的方法。

USPTO Abstract

本公开涉及包括N‑[5‑(3,5‑二氟苄基)‑1H‑吲唑‑3‑基]‑4‑(4‑甲基‑哌嗪‑1‑基)‑2‑(四氢‑2H‑吡喃‑4‑基氨基)‑苯甲酰胺和聚合物的药物组合物，包括调配物的剂型和治疗患有癌症的受试者的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111225662B
Jurisdiction
CN
Classification
—
Expires
2022-11-22
Drug substance claim
No
Drug product claim
No
Assignee
Ignyta Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.